|
 |
|
|||||||
|
|||||||||
© 2005 The American Thoracic Society
Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease
Department of Medicine, University of British Columbia; and the James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St. Paul's Hospital, Vancouver, British Columbia, Canada
Correspondence and requests for reprints should be addressed to S. F. Paul Man, M.D., Room 548, Burrard Building, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y7, Canada. E-mail: pman{at}providencehealth.bc.ca
Patients with chronic obstructive pulmonary disease (COPD) are predisposed to atherosclerosis and coronary artery disease, but the underlying mechanisms are unclear. Although there is wide acceptance that atherosclerosis is related to systemic inflammation, the cause(s) and mechanism(s) of pulmonary inflammation in stable COPD remain unknown. Infectious (bacterial and viral) as well as noninfectious agents can cause acute exacerbations in COPD, and they intensify local and systemic inflammation. Although it is not known how systemic inflammation develops in stable COPD, there is good evidence to suggest that it occurs and that the intensity of systemic inflammation is linked to the severity of airflow obstruction. We postulate that systemic inflammation provides the linkage between COPD and atherosclerosis. Inhaled corticosteroids have been shown to improve health outcomes in COPD, but the mechanism by which this occurs is a pivotal and challenging question that has yet to be answered. To prove the concept that inhaled corticosteroids could suppress systemic inflammation (as exemplified by serum C-reactive protein [CRP] levels), a double-blind, placebo-controlled clinical trial was conducted in a group of patients with mild to moderate COPD. We found that withdrawal of inhaled corticosteroids increased serum CRP levels, and that reintroduction of inhaled fluticasone could suppress CRP levels.
Key Words: C-reactive protein • chronic obstructive pulmonary disease • corticosteroid • systemic inflammation
This article has been cited by other articles:
|
|
 |
|
  E. S. Mendes, G. Horvath, P. Rebolledo, M. E. Monzon, S. M. Casalino-Matsuda, and A. Wanner Effect of an inhaled glucocorticoid on endothelial function in healthy smokers J Appl Physiol, July 1, 2008; 105(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M T Dransfield, S M Rowe, J E Johnson, W C Bailey, and L B Gerald Use of {beta} blockers and the risk of death in hospitalised patients with acute exacerbations of COPD Thorax, April 1, 2008; 63(4): 301 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Soyseth, P. H. Brekke, P. Smith, and T. Omland Statin use is associated with reduced mortality in COPD Eur. Respir. J., February 1, 2007; 29(2): 279 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Hurst, G. C. Donaldson, W. R. Perera, T. M. A. Wilkinson, J. A. Bilello, G. W. Hagan, R. S. Vessey, and J. A. Wedzicha Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 867 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Anderson COPD, asthma and C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 874 - 876. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |